Ultragenyx Pharmaceutical
Develops and commercializes therapies for serious rare and ultra-rare genetic diseases.
$25.68
After-hours close+0.07 (+0.27%)
At close$25.61(−2.48%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.63 | — | — |
| Aug 2026 | −$1.22 | −$0.90 | +26.2% |
| May 2026 | −$1.49 | −$1.84 | −23.7% |
| Feb 2026 | −$1.20 | −$1.29 | −7.5% |
| Nov 2025 | −$1.23 | −$1.81 | −47.2% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Jul 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Jul 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | −$0.63 | — | — | $184.1M | — | — |
| Aug 4, 2026 | −$1.22 | −$0.90 | +26.2% | $183.1M | $214.0M | +16.9% |
| May 5, 2026 | −$1.49 | −$1.84 | −23.7% | $158.2M | $136.0M | −14.0% |
| Feb 12, 2026 | −$1.20 | −$1.29 | −7.5% | $198.6M | $207.0M | +4.2% |
| Nov 4, 2025 | −$1.23 | −$1.81 | −47.2% | $199.8M | $159.9M | −19.9% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 5, 2025 | ||||||
| May 6, 2025 | ||||||
| Feb 13, 2025 | ||||||
| Nov 5, 2024 | ||||||
| Aug 1, 2024 | ||||||
| May 2, 2024 | ||||||
| Feb 15, 2024 | ||||||
| Nov 2, 2023 | ||||||
| Aug 3, 2023 | ||||||
| May 4, 2023 | ||||||
| Feb 16, 2023 | ||||||
| Nov 2, 2022 | ||||||
| Jul 28, 2022 | ||||||
| May 5, 2022 | ||||||
| Feb 10, 2022 | ||||||
| Nov 2, 2021 | ||||||
| Aug 2, 2021 | ||||||
| May 4, 2021 | ||||||
| Feb 11, 2021 | ||||||
| Oct 27, 2020 | ||||||
| Jul 30, 2020 | ||||||
| May 6, 2020 | ||||||
| Feb 13, 2020 | ||||||
| Nov 5, 2019 | ||||||
| Aug 1, 2019 | ||||||
| May 6, 2019 | ||||||
| Feb 19, 2019 | ||||||
| Nov 5, 2018 | ||||||
| Aug 2, 2018 | ||||||
| May 7, 2018 | ||||||
| Feb 20, 2018 | ||||||
| Nov 2, 2017 | ||||||
| Jul 27, 2017 | ||||||
| May 4, 2017 | ||||||
| Feb 16, 2017 | ||||||
| Nov 7, 2016 | ||||||
| Aug 8, 2016 | ||||||
| May 9, 2016 | ||||||
| Feb 25, 2016 | ||||||
| Nov 9, 2015 | ||||||
| Aug 13, 2015 | ||||||